Neumora Therapeutics, Inc. (NMRA:NASDAQ) closed at $0.393 on October 26, 2026, up 3.56% on the day. The stock trades 89.2% below its 52-week high of $3.65 and 24.7% above its 52-week low of $0.315. Over the past year, it lost 85.4%. Neumora Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 24, 2025, NMRA closed higher on 100 days (40%). Its best day was June 16, 2026 (+70.49%) and its worst was June 15, 2026 (-48.60%). The stock moved 10% or more in a single session 22 times. It opened at least 5% above the previous day's high 1 time.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
Find more stocks like NMRA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.